Advanced

Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study

Stuparu, Andreea D. ; Meyer, Catherine A.L. ; Evans-Axelsson, Susan L. LU ; Lückerath, Katharina ; Wei, Liu H. ; Kim, Woosuk ; Poddar, Soumya ; Mona, Christine E. ; Dahlbom, Magnus and Girgis, Mark D. , et al. (2020) In Theranostics 10(6). p.2612-2620
Abstract

225Ac-PSMA-617 targeted-therapy has demonstrated efficacy in 75-85% of patients; however, responses are not durable. We aimed to establish translatable mouse models of disseminated prostate cancer (PCa) to evaluate effectiveness of 225Ac-PSMA-617 at various disease stages. Methods: C4-2, C4-2B, or 22Rv1 cells were injected into the left ventricle of male NSG mice. Disease progression was monitored using bioluminescence imaging (BLI). For treatment, mice were injected with 40 kBq 225Ac-PSMA-617 at one (early treatment cohort) or three weeks (late treatment cohort) post-inoculation. Treatment efficacy was monitored by BLI of whole-body tumor burden. Mice were sacrificed based on body conditioning score.... (More)

225Ac-PSMA-617 targeted-therapy has demonstrated efficacy in 75-85% of patients; however, responses are not durable. We aimed to establish translatable mouse models of disseminated prostate cancer (PCa) to evaluate effectiveness of 225Ac-PSMA-617 at various disease stages. Methods: C4-2, C4-2B, or 22Rv1 cells were injected into the left ventricle of male NSG mice. Disease progression was monitored using bioluminescence imaging (BLI). For treatment, mice were injected with 40 kBq 225Ac-PSMA-617 at one (early treatment cohort) or three weeks (late treatment cohort) post-inoculation. Treatment efficacy was monitored by BLI of whole-body tumor burden. Mice were sacrificed based on body conditioning score. Results: C4-2 cells yielded metastases in liver, lungs, spleen, stomach, bones, and brain - achieving a clinically relevant model of widespread metastatic disease. The disease burden in the early treatment cohort was stable over 27 weeks in 5/9 mice and progressive in 4/9 mice. These mice were sacrificed due to brain metastases. Median survival of the late treatment cohort was superior to controls (13 vs. 7 weeks; p<0.0001) but inferior to that in the early treatment cohort (13 vs. 27 weeks; p<0.001). Late cohort mice succumbed to extensive liver involvement. The 22Rv1 and C4-2B systemic models were not used for treatment due to high kidney metastatic burden or low take rate, respectively. Conclusion: C4-2 cells reproduced metastatic cancer spread most relevantly. Early treatment with 225Ac-PSMA-617 prevented liver metastases and led to significant survival benefit. Late treatment improved survival without reducing tumor burden in the liver, the main site of metastasis. The current findings suggest that early 225Ac-PSMA-617 intervention is more efficacious in the setting of widespread metastatic PCa.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Actinium, Metastatic mouse model, Prostate cancer, PSMA, Targeted alpha therapy
in
Theranostics
volume
10
issue
6
pages
9 pages
publisher
Ivyspring International Publisher
external identifiers
  • scopus:85079687942
  • pmid:32194823
ISSN
1838-7640
DOI
10.7150/thno.42228
language
English
LU publication?
yes
id
5b019e87-ec9e-4acb-92ad-df648a53c6a6
date added to LUP
2020-03-05 11:07:47
date last changed
2021-02-17 07:22:39
@article{5b019e87-ec9e-4acb-92ad-df648a53c6a6,
  abstract     = {<p><sup>225</sup>Ac-PSMA-617 targeted-therapy has demonstrated efficacy in 75-85% of patients; however, responses are not durable. We aimed to establish translatable mouse models of disseminated prostate cancer (PCa) to evaluate effectiveness of <sup>225</sup>Ac-PSMA-617 at various disease stages. Methods: C4-2, C4-2B, or 22Rv1 cells were injected into the left ventricle of male NSG mice. Disease progression was monitored using bioluminescence imaging (BLI). For treatment, mice were injected with 40 kBq <sup>225</sup>Ac-PSMA-617 at one (early treatment cohort) or three weeks (late treatment cohort) post-inoculation. Treatment efficacy was monitored by BLI of whole-body tumor burden. Mice were sacrificed based on body conditioning score. Results: C4-2 cells yielded metastases in liver, lungs, spleen, stomach, bones, and brain - achieving a clinically relevant model of widespread metastatic disease. The disease burden in the early treatment cohort was stable over 27 weeks in 5/9 mice and progressive in 4/9 mice. These mice were sacrificed due to brain metastases. Median survival of the late treatment cohort was superior to controls (13 vs. 7 weeks; p&lt;0.0001) but inferior to that in the early treatment cohort (13 vs. 27 weeks; p&lt;0.001). Late cohort mice succumbed to extensive liver involvement. The 22Rv1 and C4-2B systemic models were not used for treatment due to high kidney metastatic burden or low take rate, respectively. Conclusion: C4-2 cells reproduced metastatic cancer spread most relevantly. Early treatment with <sup>225</sup>Ac-PSMA-617 prevented liver metastases and led to significant survival benefit. Late treatment improved survival without reducing tumor burden in the liver, the main site of metastasis. The current findings suggest that early <sup>225</sup>Ac-PSMA-617 intervention is more efficacious in the setting of widespread metastatic PCa.</p>},
  author       = {Stuparu, Andreea D. and Meyer, Catherine A.L. and Evans-Axelsson, Susan L. and Lückerath, Katharina and Wei, Liu H. and Kim, Woosuk and Poddar, Soumya and Mona, Christine E. and Dahlbom, Magnus and Girgis, Mark D. and Radu, Caius G. and Czernin, Johannes and Slavik, Roger},
  issn         = {1838-7640},
  language     = {eng},
  month        = {02},
  number       = {6},
  pages        = {2612--2620},
  publisher    = {Ivyspring International Publisher},
  series       = {Theranostics},
  title        = {Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study},
  url          = {http://dx.doi.org/10.7150/thno.42228},
  doi          = {10.7150/thno.42228},
  volume       = {10},
  year         = {2020},
}